Hiroshi Yamashita
Institute for Drug Discovery Research
Yamanouchi Pharmaceutical Co.
Ltd, Tsukuba
Ibaraki
Japan
Name/email consistency: high
- Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. Yamashita, H., Ohno, K., Amada, Y., Hattori, H., Ozawa-Funatsu, Y., Toya, T., Inami, H., Shishikura, J., Sakamoto, S., Okada, M., Yamaguchi, T. J. Pharmacol. Exp. Ther. (2004)
- Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy. Yamashita, H., Ohno, K., Inami, H., Shishikura, J., Sakamoto, S., Okada, M., Yamaguchi, T. Eur. J. Pharmacol. (2004)
- Effect of YM928, a novel AMPA receptor antagonist, on seizures in EL mice and kainate-induced seizures in rats. Yamashita, H., Ohno, K., Amada, Y., Inami, H., Shishikura, J., Sakamoto, S., Okada, M., Yamaguchi, T. Naunyn Schmiedebergs Arch. Pharmacol. (2004)